A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

计划入组 54 人 · 首次发布于 2013 年 10 月 7 日

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

计划入组 9 人 · 首次发布于 2024 年 6 月 27 日

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

计划入组 9 人 · 首次发布于 2024 年 7 月 3 日

NW-102

NW-103

NW-104

Angel Yeast Co.,Ltd

China

Thrasher Research Fund

United States

The Jimmy Fund

United States

Combat Medical Advances HIVEC HEAT Trial for BCG-Unresponsive Bladder Cancer with £2.6 Million Series A Funding

Angel Pharmaceuticals Receives China IND Approval for Soquelitinib Atopic Dermatitis Trial

Angel Yeast Advances Biomanufacturing with New Biotechnology Park Set for September Launch